Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol
Arimoclomol had no significant effects on the qMRI measurements evaluated, consistent with clinical outcomes from the main trial. The qMRI measurements demonstrated both validity and responsiveness, further supporting their potential utility as biomarkers in IBM.
Authors
- Michael G. Hanna (ORCID: https://orcid.org/0000-0003-0825-4075)
- John S. Thornton (ORCID: https://orcid.org/0000-0003-3248-8437)
- Richard J. Barohn (ORCID: https://orcid.org/0000-0002-0383-6845)
- Mazen M. Dimachkie (ORCID: https://orcid.org/0000-0002-7148-989X)
- Jasper M. Morrow (ORCID: https://orcid.org/0000-0001-6879-8539)
- Nikolaos Zafeiropoulos (ORCID: https://orcid.org/0000-0002-8682-3774)
- Stephen Wastling (ORCID: https://orcid.org/0000-0003-4648-9932)
- Pedro Machado (ORCID: https://orcid.org/0000-0002-8411-7972)
- Tarek Yousry (ORCID: https://orcid.org/0000-0003-3295-0628)
- Michael P. McDermott (ORCID: https://orcid.org/0000-0001-7443-9145)
- Sachit Shah
- Sharfaraz Salam
Institutions
- University of Rochester Medical Center (US)
- UCL Biomedical Research Centre (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Missouri (US)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.55563/clinexprheumatol/5b9lme
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35